Finally, deruxtecan (DX-d), an anti-topoisomerase 1 (TOP1) compound, is the warhead of the anti-HER2 trastuzumab deruxtecan (T-DXd), which has been approved for BC and gastric cancer, while being under development for several tumor types [25]. This evidence concerns the gene ERBB2 and gastric cancer.